

CITATION REPORT

List of articles citing

Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis

DOI: 10.1007/s11239-014-1104-3

Journal of Thrombosis and Thrombolysis, 2015, 39, 149-54.

Source: <https://exaly.com/paper-pdf/61768947/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	A grammar-based approach to model the patient's clinical trajectory after a mild traumatic brain injury. 2015 ,		2
27	Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. <i>Clinical Therapeutics</i> , 2015 , 37, 2476-2488.e27	3.5	5
26	New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. <i>Therapeutics and Clinical Risk Management</i> , 2015 , 11, 967-77	2.9	227
25	Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 811-24	2.5	5
24	Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. <i>Pharmacoeconomics</i> , 2015 , 33, 395-408	4.4	37
23	Edoxaban: a review in nonvalvular atrial fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2015 , 15, 351-61	4	4
22	Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2661-78	4	2
21	Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAf) in the US. <i>ClinicoEconomics and Outcomes Research</i> , 2016 , 8, 215-26	1.7	13
20	Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. <i>Pharmacotherapy</i> , 2016 , 36, 488-95	5.8	13
19	Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. <i>Future Cardiology</i> , 2016 , 12, 419-33	1.3	4
18	Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2016 , 47, 1555-61	6.7	37
17	Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation. <i>Applied Health Economics and Health Policy</i> , 2016 , 14, 313-22	3.4	3
16	Individualized approaches to thromboprophylaxis in atrial fibrillation. <i>American Heart Journal</i> , 2016 , 173, 143-58	4.9	9
15	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 221-35	2.2	16
14	Edoxaban in patients with atrial fibrillation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017 , 11, 81-90	3.4	3
13	Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017 , 23, 685-695	3.3	0
12	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017 , 34, 620-637	4.1	6

11	Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?. <i>American Journal of Medicine</i> , 2017 , 130, 900-906	2.4	4
10	Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban. <i>International Journal of Neuroscience</i> , 2017 , 127, 716-725	2	2
9	Managing patients taking edoxaban in dentistry. <i>Journal of Clinical and Experimental Dentistry</i> , 2017 , 9, e308-e311	1.4	5
8	Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019 , 72, 398-406	0.7	3
7	¿El uso de edoxabán será coste-efectivo para la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular en España?. <i>Revista Espanola De Cardiologia</i> , 2019 , 72, 398-406	1.5	4
6	Edoxaban for the prevention of stroke in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 319-330	2.5	6
5	Perioperative Dental Management of Patients in The Background of Antithrombotic Use. <i>Current Research in Dentistry</i> , 2019 , 1, 30-39	0.5	
4	Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation. <i>ClinicoEconomics and Outcomes Research</i> , 2021 , 13, 745-755	1.7	3
3	Determination of Edoxaban in Bulk and in Tablet Dosage Form by Stability Indicating High-Performance Liquid Chromatography. <i>Pharmaceutical Sciences</i> , 2016 , 22, 35-41		4
2	Critical Issues and Recent Advances in Anticoagulant Therapy: A Review. <i>Neurology India</i> , 2019 , 67, 1200-1212	1.2	3
1	Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. <i>BMJ Evidence-Based Medicine</i> , 2021 ,	2.7	4